Abiopharma

(90% Positive) VANDA PHARMACEUTICALS INC. (VNDA) Provides Update on effectiveness for Jet Lag DisorderJanuary 8

(90% Positive) CLIMB BIO, INC. (ELYM) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Canopy Growth Communication - Canopy Growth Announces Strategic Recapitalization Transactions Significantly Strengthening Balance Sheet to Support Growth Strategy

(90% Positive) AMARIN CORP PLC\UK (AMRN) Provides Update on meetings for our operating expenses

(10% Negative) AMYLYX PHARMACEUTICALS, INC. (AMLX) Files Form 8-K

(10% Negative) Neogen Corporation (NEOG) Reports Q1 2026 Financial Results

Veeva Announces Environmental Monitoring Solution to Modernize Quality Control in Manufacturing

Anika Therapeutics Announces Leadership Transition

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Bruker - Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria